A stripped-down version of the US Food and Drug Administration user-fee reauthorization package newly introduced in the Senate leaves out proposed diagnostics regulatory reform, marking yet another roadblock for the FDA’s ongoing efforts to bring regulation of more lab tests in-house.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?